Enhertu has been granted breakthrough therapy designation in the U.S. for adult patients with HER2 positive early breast cancer with residual invasive disease in the breast and/or axillary lymph nodes after neoadjuvant treatment and high risk of disease recurrence. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate discovered by Daiichi Sankyo and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (AZN).
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AZN:
- Drugmakers set to make deals with Trump in exchange for incentives, WaPo reports
- Niowave expands global supply agreement with AstraZeneca for Actinium-225
- TROPION-Lung17: New Phase III Lung Cancer Trial Adds Medium-Term Upside Potential for AstraZeneca and Daiichi Sankyo
- AstraZeneca Targets Costly C. Diff Recurrence With New Antibody Trial
- AstraZeneca’s AZD1163 Trial Adds Quiet Option Value in Rheumatoid Arthritis